iJOBS Career Panel: Science Policy
Tuesday, January 25, 2022
10:30 AM

Joseph B. Keller, Ph.D.
Senior Director of Congressional and Federal Relations
American Psychological Association (APA)
joseph.keller1@gmail.com

Joseph B. Keller is a trained neuroscientist and works in science policy and advocacy as a Senior Director of Congressional and Federal Relations at the American Psychological Association (APA). Here, he manages a portfolio of agencies like the National Science Foundation and Department of Transportation, and legislative issues like artificial intelligence and climate change – topics relevant to psychological science. Prior to APA, Joseph was an AAAS Science and Technology Policy Fellow at the National Science Foundation where he supported grant making programs from computational neuroscience to artificial intelligence. He also served as a nonprofit executive search consultant, conducting leadership searches for institutions in higher education, academic medicine, philanthropy, and environmental conservation. Joseph holds a PhD from the Massachusetts Institute of Technology, a MA from Boston University, and a BS from the University of Maryland, Baltimore County. He sits on the Board of the STEM Advocacy Institute.

Michael A. Fisher, PhD
Senior Fellow
Federation of American Scientists
mfisher@fas.org

Michael A. Fisher, Ph.D., is a senior fellow with the Federation of American Scientists, working on a range of issues across the science and technology policy landscape. With scientific training at Rutgers-New Jersey Medical School, UC Berkeley, and Princeton, Dr. Fisher has developed technical expertise in infectious disease research, biofuels, synthetic biology, protein engineering, and molecular biology. In 2018, he served as a field director with a congressional campaign. Dr. Fisher earned his B.S. in Biology from The College of New Jersey and his Ph.D. in Molecular Biology from Princeton University.

Trisha Chakraborty, PhD
Health Science Policy Analyst
National Institutes of Health's Office of Science Policy
trishchakra07@gmail.com

Dr. Trisha Chakraborty is a Health Science Policy Analyst in the National Institutes of Health's Office of Science Policy. Her portfolio covers public-private partnerships, congressional and departmental audits, oversight of NIH's efforts with the White House Office of Science and Technology Policy, and tribal health policy. Trisha left the bench to explore the field of science policy as a AAAS Science and Technology Policy Fellow at the Department of Justice. There she worked on topics ranging from tribal justice issues, firearms, forensic intelligence, metal health among first responders, and criminal justice research. Trisha graduated with a Ph.D. in behavioral neuroscience from the University of Delaware where she studied molecular neurobiology of fear learning and memory in animal models.

Megan Anderson Brooks, Ph.D.
Principal
Innovation Policy Solutions LLC
megan@ipolicysolutions.com

Megan Anderson Brooks, a Principal at Innovation Policy Solutions LLC, lobbies and consults on a broad range of health and science policy issues. Leveraging her expertise as a researcher in the field of neuroscience for over ten years, she specializes in implementing federal policy solutions that help create, advance, and result in the adoption of technological innovations. She previously served as Vice President at CRD Associates, and additionally, advocated on behalf of the neuroscience research community while at the Society for Neuroscience. During an Eagleton Institute of Politics awarded fellowship placement at the New Jersey Department of Health, she partnered with colleagues in the development of a successful CDC-awarded program to prevent and control chronic disease in the state. Megan holds a Ph.D. in neuroscience from Rutgers University.

Brian Canter, Ph.D.
Senior Policy Analyst
Duke-Margolis
bcanter89@gmail.com

Brian Canter is a Senior Policy Analyst working on policy issues related to biomedical innovation and COVID-19 therapies. He planned and organized a workshop on opioid prescriber education that had over 400 attendees across two days. In addition, he coauthored issue briefs on equitable state allocation of monoclonal antibodies to treat COVID-19 and the effect of automatic substitution—at the retail pharmacy setting—on

biosimilar adoption. Currently, he is working on key issues for consideration ahead of regulatory authorization for oral antiviral treatments for COVID-19. Prior to joining Duke-Margolis, Brian completed a PhD in Biomedical Sciences with a focus in Biomedical Engineering from Rutgers University. His thesis research focused on utilizing radiation therapy systemically to treat metastatic breast cancer that spread to bone. Brian also graduated with a Bachelor's degree in Biomedical Engineering from Tufts University.